Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha; Murat Yalcin; Hung Yun Lin; Ahmed M. Elmetwally; Tipu Nazeer; Thiruvengadam Arumugam; Patricia Phillips; Shaker A. Mousa

doi:10.1016/j.canlet.2014.04.016

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha
, Murat Yalcin
, Hung Yun Lin
, Ahmed M. Elmetwally
, Tipu Nazeer
, Thiruvengadam Arumugam
, Patricia Phillips
, Shaker A. Mousa

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

Original language	English
Pages (from-to)	25-33
Number of pages	9
Journal	Cancer Letters
Volume	350
Issue number	1-2
DOIs	https://doi.org/10.1016/j.canlet.2014.04.016
Publication status	Published - Aug 1 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anti-cancer
Low molecular weight heparin
Non-anticoagulant heparin
Pancreatic cancer
Tumor suppressor
Tumor survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2014.04.016

Cite this

@article{aaa08a5899344cf28f9a90d5a131952d,

title = "Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin",

abstract = "Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.",

keywords = "Anti-cancer, Low molecular weight heparin, Non-anticoagulant heparin, Pancreatic cancer, Tumor suppressor, Tumor survival",

author = "Thangirala Sudha and Murat Yalcin and Lin, \{Hung Yun\} and Elmetwally, \{Ahmed M.\} and Tipu Nazeer and Thiruvengadam Arumugam and Patricia Phillips and Mousa, \{Shaker A.\}",

note = "Funding Information: This work was supported by the National Institutes of Health (Grant Number 1R21CA124931-01 to S.A.M.). We appreciate the excellent editing by Dr. Kelly A. Keating, Pharmaceutical Research Institute (PRI) and the technical support by members of the PRI.",

year = "2014",

month = aug,

day = "1",

doi = "10.1016/j.canlet.2014.04.016",

language = "English",

volume = "350",

pages = "25--33",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1-2",

}

TY - JOUR

T1 - Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

AU - Sudha, Thangirala

AU - Yalcin, Murat

AU - Lin, Hung Yun

AU - Elmetwally, Ahmed M.

AU - Nazeer, Tipu

AU - Arumugam, Thiruvengadam

AU - Phillips, Patricia

AU - Mousa, Shaker A.

N1 - Funding Information: This work was supported by the National Institutes of Health (Grant Number 1R21CA124931-01 to S.A.M.). We appreciate the excellent editing by Dr. Kelly A. Keating, Pharmaceutical Research Institute (PRI) and the technical support by members of the PRI.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

AB - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

KW - Anti-cancer

KW - Low molecular weight heparin

KW - Non-anticoagulant heparin

KW - Pancreatic cancer

KW - Tumor suppressor

KW - Tumor survival

UR - https://www.scopus.com/pages/publications/84901494319

UR - https://www.scopus.com/pages/publications/84901494319#tab=citedBy

U2 - 10.1016/j.canlet.2014.04.016

DO - 10.1016/j.canlet.2014.04.016

M3 - Article

C2 - 24769074

AN - SCOPUS:84901494319

SN - 0304-3835

VL - 350

SP - 25

EP - 33

JO - Cancer Letters

JF - Cancer Letters

IS - 1-2

ER -

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this